Zydus Lifesciences received 5 observations from the US Food and Drug Administration following an inspection at its Moraiya plant, with the company stating plans to resolve the issues quickly.

Inspection outcome at Moraiya facility

The USFDA inspection at the Moraiya plant concluded with 5 observations issued to Zydus Lifesciences. The company has communicated its intent to address and resolve the observations promptly.

Company's stated response

Zydus Lifesciences indicated it plans to resolve the observations quickly. No further details regarding the nature of the individual observations or a specific resolution timeline were provided in the available information.

Regulatory disclosure details

The company disclosed the inspection conclusion pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The press release was signed by Dhaval N. Soni, Company Secretary and Compliance Officer.

Zydus Lifesciences , in partnership with MSN Laboratories, launched the first generic version of Adempas (Riociguat Tablets) in the United States on October 5, 2026.

Launch details and market impact

The jointly launched product marks the first generic entry for Riociguat Tablets in the US market. The collaboration brings this generic version to American patients living with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Zydus and MSN are the first companies to launch a generic version of Adempas in the US.

The launch represents a significant milestone for both companies. Being first to market with a generic equivalent typically provides a competitive advantage in the US pharmaceutical space. The product was developed and is manufactured by MSN, leveraging their integrated API and formulation R&D capabilities.

Clinical indications and regulatory approval

Riociguat Tablets are approved by the United States Food and Drug Administration (USFDA) as a generic equivalent of Adempas Tablets in all five strengths. Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for adults with persistent or recurrent CTEPH (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. It is also indicated for adults with PAH (WHO Group 1) to improve exercise capacity, improve WHO functional class, and delay clinical worsening.

Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, stated that being first to market reflects the strength of their complex-generics pipeline and ability to execute day-one launches in specialty categories. Dr. MSN Reddy, Founder & CMD, MSN Laboratories, highlighted that riociguat is a technically demanding molecule, demonstrating the depth of MSN's manufacturing scale.

Market context

PAH and CTEPH are rare, progressive, and life-threatening conditions where patients typically remain on therapy for life. Until this launch, riociguat was available in the United States only as the branded product. According to Bayer's Annual Report 2025, global sales of Adempas were approximately EUR 745 million (approximately USD 850 million) in 2025. Sales of riociguat are not reported by IQVIA.